Skip to content
Visionary Ventures
Venture capital fund investing life sciences focusing in ophthalmology medical devices and pharmaceuticals.
Visionary VenturesVisionary Ventures
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN
Fund Menu
Search
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN

Monthly Archives: April 2020

Robert Dempsey the New CEO of TearClear Interviewed on OIS Podcast

News, TearClearBy Garrett HamontreeApril 21, 2020

In this week’s OIS Podcast, Dr. Ehsan Sadri speaks with Bob Dempsey who just assumed the CEO role for TearClear. Let’s hear how Bob’s experience taking Xiidra to market for Shire led him to the driver’s seat for one of the most promising new drug-delivery companies.

TearClear Completes Initial Close of $25MM Series B Financing

News, TearClearBy Garrett HamontreeApril 16, 2020

TearClear Completes Initial Close of $25MM Series B Financing led by Visionary Ventures, Bluestem Capital, and Flying L. Additionally, TearClear has appointed Robert Dempsey to the CEO role. Robert Dempsey and Bill Link were interviewed by Eyewire news about the latest financing and CEO appointment.

Jeffry Weinhuff, Visionary Managing Partner, Interviewed about Life Science Investing for the Long Haul

News, VisionaryBy Garrett HamontreeApril 10, 2020

Q&A with Jeffry Weinhuff from Visionary Ventures on how life science investors view the current COVID-19 climate, what opportunities might arise, and what health care innovations are more important now more than ever.

  • Home
  • Ophthalmology
  • Team
    • Investment Committee
    • Visionary KOLs
    • Fund Management
  • Portfolio
  • News
  • Contact
  • Investor Portal
Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.

Go to Top